Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

The Lancet. Oncology - 1 Apr 2018

Garassino Marina Chiara, Cho Byoung-Chul, Kim Joo-Hang, Mazières Julien, Vansteenkiste Johan, Lena Hervé, Corral Jaime Jesus, Gray Jhanelle E, Powderly John, Chouaid Christos, Bidoli Paolo, Wheatley-Price Paul, Park Keunchil, Soo Ross A, Huang Yifan, Wadsworth Catherine, Dennis Phillip A, Rizvi Naiyer A

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors are a new standard of care for patients with advanced non-small-cell lung cancer (NSCLC) without EGFR tyrosine kinase or anaplastic lymphoma kinase (ALK) genetic aberrations (EGFR-/ALK-), but clinical benefit in patients with EGFR mutations or ALK rearrangements (EGFR+/ALK+) has not been shown. We assessed the effect of durvalumab (anti-PD-L1) treatment in three cohorts of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 4-Butyrolactone
Share to Anaplastic Lymphoma Kinase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to Aspartate Aminotransferases

Share to Fatigue

Share to gamma-Glutamyltransferase

Share to Pneumonia

Share to Progression-Free Survival

Source

Open in PubMed Open full text

Identifiers

PMID: 29545095
DOI: 10.1016/S1470-2045(18)30144-X
PMCID: PMC7771363

Genes

EGFR
ALK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.PMID 29545095Read ↗

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.Semantic proximity Read ↗

Atezolizumab in combination with bevacizumab, paclitaxel and carboplatin for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, including patients with EGFR mutations.Semantic proximity Read ↗

PD-L1 as a Biomarker for the Efficacy of Durvalumab in Stage III EGFR Mutant NSCLC.Semantic proximity Read ↗

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.Semantic proximity Read ↗

Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD.Semantic proximity Read ↗

Influence of EGFR mutation status and PD-L1 expression in stage III unresectable non-small cell lung cancer treated with chemoradiation and consolidation durvalumab.Semantic proximity Read ↗

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).Semantic proximity Read ↗

Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR-mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis.Semantic proximity Read ↗

Impact of TMB, PD-L1 expression, and pneumonitis on outcomes to chemoradiation and durvalumab in unresectable stage III non-small cell lung cancersSemantic proximity Read ↗

Evaluating datopotamab deruxtecan (Dato-DXd) as a novel treatment option for EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.